AURKA and chronic myelogenous leukemia, BCR-ABL1 positive: In the context of resistance to TKIs, an AURKA/AURKB inhibitor has been reported to induce senescence in chronic myeloid leukemia cells carrying the imatinib-resistant T315I mutation in ABL50.